Case Report

Postliver Transplantation Rhino-Orbital Mucormycosis, an Unexpected Cause of a Downhill Course

Swapnali Sabhapandit, 1 Mithun Sharma 2, Anuradha Sekaran, 3 Balachandran Menon, 4 Anand Kulkarni, 2 Soumya TR, 2 Padaki Nagaraja Rao, 2 and Duvurr Nageshwar Reddy 5

1 Department of Ophthalmology, AIG Hospitals, Hyderabad, India
2 Department of Hepatology and Liver Transplantation, Asian Institute of Gastroenterology, Hyderabad, India
3 Department of Pathology, Asian Institute of Gastroenterology, Hyderabad, India
4 Department of Liver Transplantation, Asian Institute of Gastroenterology, Hyderabad, India
5 Department of Gastroenterology, Asian Institute of Gastroenterology, Hyderabad, India

Correspondence should be addressed to Mithun Sharma; drmithunsharma@gmail.com

Received 23 February 2022; Revised 4 April 2022; Accepted 15 May 2022; Published 28 May 2022

Academic Editor: Haruki Komatsu

Copyright © 2022 Swapnali Sabhapandit et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The COVID-19 pandemic has impacted transplantation worldwide in a major way with infections and post-COVID-19 complications contributing to increased mortality and morbidity. We present a case of a 42-year-old lady who developed rhino-orbital mucormycosis in a postliver transplantation period. The initial presentation of the patient was very subtle. She never had overt COVID-19 infection before surgery and in the recovery period. Though cases of mucormycosis in the wound site have been reported, this would be one of the rare cases of rhino-orbital mucormycosis postliver transplantation. This infection leads to a rapid downhill course and the death of the patient. Atypical infections and presentations need to be monitored in postliver transplantation patients who are getting operated on during this pandemic, and a high level of clinical suspicion is required to pick up these cases at an early stage.

1. Introduction

Coronavirus disease-2019 (COVID-19) pandemic has affected liver transplantation programmes worldwide and has thrown new challenges in both the pre and post-transplantation periods. Though, currently, many guidelines are in place, yet in the initial phase of pandemic, weighing the risk-benefit ratio of transplantation versus adverse outcome due to SARS-CoV-2 infection was tough [1].

Postliver transplantation outcome has shown varied results during the pandemic. In a systematic review, 23% of posttransplantation patients were found to be infected with severe COVID-19 infection with 55.9% cases requiring modification of immunosuppression [2]. In addition, recent data from the West have shown “excess deaths” in all solid organ transplantations during the pandemic, with the number of deaths mirroring the COVID-19 incidence [3].

In India, during the second wave of the COVID-19 pandemic, rhino-orbital mucormycosis was increasingly reported in diabetic patients (81.2%) and patients with corticosteroid use (79.69%) requiring oxygen supplementation [4]. However, in the published case series, no case was reported in postliver transplantation patients, though they too had a common risk factor of use of corticosteroids. The worst prognosis has been noted in patients with involvement of the brain and those who had a SOFA score of greater than 2 at presentation [5].

We present a case of rhino-orbital mucormycosis in a postliver transplantation patient. The case brings to forefront the subtle onset of the disease and the need of high
index of clinical suspicion for diagnosis. Early diagnosis can save the life of many of these patients with good outcome [6].

2. Case Report

We present a case of a 42-year-old gentleman who underwent living donor liver transplantation on 25th May 2021 for alcohol use disorder-related decompensated chronic liver disease with MELD score 28. The ABO compatible donor was his wife who had no comorbidities except for hypothyroidism. Both the donor and the recipient were negative for severe acute respiratory syndrome virus 2 (SARS-CoV-2) on reverse transcriptase polymerase chain reaction (RT-PCR) done on two occasions with the last test done 24 hours before surgery. As per protocol of our institute, the COVID-19 antibodies were also tested and found to be negative 24 hours prior to liver transplantation. Neither the recipient nor the donor was vaccinated against SARS-CoV-2.

The postoperative recovery period was uneventful, and the patient was treated with steroids, tacrolimus, and mycophenolate mofetil as per protocol. The dose of prednisolone was tapered to 15 mg/day on the fifteenth day postsurgery. The patient did not have any fever or constitutional symptoms in the postoperative period. However, on posttransplantation day 20, he complained of sudden onset redness of the left periorbital area with pain in the left eye (Figure 1(a)). An immediate in-house ophthalmology consultation was sought. On examination, there was ptosis of the left upper eyelid and mild proptosis of the left eye along with conjunctival redness. Contrast-enhanced magnetic resonance imaging of the orbit, paranasal sinuses, and the brain showed thickening of the medial rectus and superior oblique muscles with fat stranding. In addition, contiguous areas of nonenhancing tissue were noted in the paranasal sinuses suggestive of angioinvasive fungal infection (Figure 1(b)). Qualitative PCR from swabs taken from the left nostril was positive for Mucorales deoxyribonucleic acid, which is a sensitive marker for invasive mucormycosis. His repeat test for SARS-CoV-2 RT-PCR and rapid antigen tests were negative. However, his immunoglobulin (Ig) G for COVID-19 was now positive, while IgM was negative. A computerized tomography of the chest showed no evidence of pulmonary COVID-19 infection or any pulmonary mucormycosis.

Nasal swab stain revealed hyphae of mucormycosis on Grocott methenamine silver stain (Figure 1(c)). Based on reports of nasal swab, positive DNA for Mucorales and radiographic features [7], a diagnosis of rhino-orbital mucormycosis was made. Systemic antifungals (intravenous liposomal-amphotericin B, 10 mg/kg/day, with oral posaconazole 300 mg twice daily on day 1 followed by 300 mg once daily) were initiated. Immunosuppressants tacrolimus and mycophenolate mofetil were stopped. However, even after five days of initiation of antifungals, the patient did not show any clinical signs of improvement. A repeat contrast enhanced MRI of the orbit and paranasal sinuses showed worsening of the lesions with invasion of the orbital bone. Orbital exenteration with the eyelid sparing technique was planned, but surgical consent was refused by the family. Despite continuing conservative management for next 3 days, the patient had a downhill course and succumbed to his infection.

Informed written consent was taken for publication of this case from the patient and also next of kin.

3. Discussion

Rhino-orbital mucormycosis is frequently caused by fungal infection due to Rhizopus spp., Mucor spp., and Lichtheimia spp. [8] During the COVID-19 pandemic, there has been an increase in the incidence of such cases [9]. The source of infection is usually from the paranasal sinuses, and majority of the patients presents with unilateral facial edema and proptosis [10]. The European Confederation of Medical Mycology (ECMM) has laid down specific guidelines for diagnosis and includes demonstration of fungal hyphae in microscopy and culture along with molecular methods for direct detection of fungal deoxyribonucleic acid [11].

Steroids use during the pandemic has been implicated as the most common predisposing factor for rhino-orbital mucormycosis [12]. Other coexisting diseases such as diabetes mellitus has been associated with majority of the cases [13]. Longer length of hospital stay in posttransplantation immunosuppressed patients may predispose them to multiple infections including mucormycosis [14]. A rare case report of rhino-orbital maxillary mucormycosis after solid organ transplantation has been reported in the non-pandemic era also [15].

Figure 1: Picture showing lid edema and ptosis of left eye lid (a) with MRI showing mucormycosis deposits in the left paranasal sinuses and orbit (b). Staining with Grocott methenamine silver stain showing septate hyphae of mucormycosis (c).
One interesting finding is that despite the use of steroids in posttransplantation patients, the reported incidence of invasive mucormycosis is rare in the nonpandemic era, and therefore, questions have been raised as to whether the SARS-CoV-2 virus itself predisposes patients to mucormycosis.

After solid organ transplantation, abdominal mucormycosis has been reported, and the most common route of infection is contamination during surgery [16]. However, in our case, since the surgical wound was not involved, the chances of contacting the infection from the operation theatre during surgery were very remote. The possibility of SARS-CoV-2 RT-PCR-negative COVID-19 infection was assumed as IgG and IgM which was negative pretransplantation changed to IgG positive posttransplantation. SARS-CoV-2 IgG positivity indicates asymptomatic COVID-19 during the recovery period, which may be masked by immunosuppressants.

Though COVID-19 is showing a downward trend, possibility of a fourth wave still looms large. This case would serve as an index case of rhino-orbital mucormycosis in postliver transplantation patients and make transplant physicians keep their index of suspicion high for any periorbital swelling or ocular pain after transplantation.

4. Conclusion

Despite extensive screening of patients in the pretransplantation period, the risk of contracting asymptomatic COVID-19 in the posttransplantation period is possible. However, the exact source and predisposing factor in this rare case will remain an enigma. High index of suspicion is required for any atypical symptom that may occur in the posttransplantation period in this era of COVID-19 pandemic.

Abbreviations

SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2
IgG: Immunoglobulin G
RT-PCR: Reverse transcriptase polymerase chain reaction

Data Availability

The data used to support this study are available from the corresponding author upon request.

Consent

Informed written consent was taken from the patient for publication of the case details.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

SS, MS, and BM conceptualized and designed the study. AS analysed the pathology specimens, AVK, SS, and MS collected data. SS and MS did compilation. MS, SS, and PNR did the initial draft. SS, AS, and MS provided figures. DNR, PNR, SS, and MS edited and revised the article. All members approved the final draft.

References

[1] S. Gupta, S. Sudhindran, N. Saraf et al., “Liver transplant society of India guidelines for liver transplant during COVID-19 times,” Journal of Clinical and Experimental Hepatology, vol. 12, no. 1, pp. 180–185, 2022.
[2] A. V. Kulkarni, H. V. Tevethia, M. Premkumar et al., “Impact of COVID-19 on liver transplant recipients—A systematic review and meta-analysis,” EClinicalMedicine, vol. 38, Article ID 101025, 2021.
[3] A. B. Massie, W. A. Werbel, R. K. Avery, T. Po-Yu Chiang, J. J. Snyder, and D. L. Segev, “Quantifying excess deaths among solid organ transplant recipients in the COVID-19 era,” American Journal of Transplantation, 2022.
[4] R. Patel, J. Jethva, P. R. Bhagat, V. Prajapati, H. Thakkar, and K. Prajapati, “Rhino-orbital-cerebral mucormycosis: an epidemiological study from a tertiary care referral center in Western India,” Indian Journal of Ophthalmology, vol. 70, no. 4, pp. 1371–1375, 2022.
[5] H. R. Nehara, S. Kumawat, J. Gupta, G. Gupta, P. Sirohi, and B. Gupta, “Coronavirus disease, diabetes and glucocorticoid a terrible trio for invasive mucormycosis: an observational study from northwest Rajasthan,” Journal of the Association of Physicians of India, vol. 69, no. 12, pp. 11-12, 2022.
[6] J. C. Deyo, N. Nicolsen, A. Lachiewicz, and T. Kozlowski, “Salvage treatment of mucormycosis post-liver transplant with Posaconazole during sirolimus maintenance immunosuppression,” Journal of Pharmacy Practice, vol. 30, no. 2, pp. 261–265, 2017.
[7] S. Sañder, J. S. Carpenter, T. D. Roberts, and N. Bailey, “The “Black Turbinate” sign: an early MR imaging finding of nasal mucormycosis,” American Journal of Neuroradiology, vol. 31, no. 4, pp. 771–774, 2010.
[8] O. A. Corney, A. Alastruey-Izquierdo, D. Arenz et al., “Global guideline for the diagnosis and management of mucormycosis: an initiative of the European confederation of medical Mycology in cooperation with the mycoses study group education and research consortium,” The Lancet Infectious Diseases, vol. 19, no. 12, pp. e405–e421, 2019.
[9] K. Ahmadikia, S. J. Hashemi, S. Khodavaisy et al., “The double-edged sword of systemic corticosteroid therapy in viral pneumonia: a case report and comparative review of influenza-associated mucormycosis versus COVID-19 associated mucormycosis,” Mycoses, vol. 64, no. 8, pp. 798–808, 2021.
[10] M. S. Bae, E. J. Kim, K. M. Lee, and W. S. Choi, “Rapidly progressive rhino-orbito-cerebral mucormycosis complicated with unilateral internal carotid artery occlusion: a case report,” Neurointervention, vol. 7, no. 1, pp. 45–49, 2012.
[11] M. Chermetz, M. Gobbo, K. Rupel et al., “Combined orofacial aspergillosis and mucormycosis: fatal complication of a recurrent paediatric glioma-case report and review of literature,” Mycopathologia, vol. 181, no. 9-10, pp. 723–733, 2016.
[12] M. Sen, S. G. Honavar, N. Sharma, and M. S. Sachdev, “COVID-19 and eye: a review of ophthalmic manifestations of COVID-19,” Indian Journal of Ophthalmology, vol. 69, no. 3, pp. 488–509, 2021.

[13] J. A. Al-Tawfiq, S. Alhumaid, A. N. Alshukairi et al., “COVID-19 and mucormycosis superinfection: the perfect storm,” Infection, vol. 49, pp. 1–21, 2021.

[14] M. Salehi, K. Ahmadikia, H. Badali, and S. Khodavaisy, “Opportunistic fungal infections in the epidemic area of COVID-19: a clinical and diagnostic perspective from Iran,” Mycopathologia, vol. 185, no. 4, pp. 607–611, 2020.

[15] R. Farojov, O. Aydin, C. Yilmaz et al., “Rhino-orbita-maxillary mucormycosis after liver transplantation: a case report,” Transplantation Proceedings, vol. 48, no. 9, pp. 3210–3213, 2016.

[16] M. Kueht, J. A. Villarreal, E. Reece et al., “Cutaneous mucormycosis in solid organ transplant recipients after hurricane harvey: short- and long-term management,” Plastic and Reconstructive Surgery—Global Open, vol. 7, no. 1, Article ID e2041, 2019.